KLRS
Price
$1.99
Change
-$0.03 (-1.49%)
Updated
Oct 22 closing price
Capitalization
47.37M
20 days until earnings call
Intraday BUY SELL Signals
MESO
Price
$12.55
Change
-$0.28 (-2.18%)
Updated
Oct 22 closing price
Capitalization
1.63B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KLRS vs MESO

KLRS vs MESO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KLRS vs. MESO commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KLRS is a Hold and MESO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KLRS with price predictions
Oct 22, 2026

KLRS in -3.86% downward trend, falling for three consecutive days on October 22, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KLRS declined for three days, in 312 of 343 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for KLRS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

KLRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.821) is normal, around the industry mean (2.973). P/E Ratio (-1.050) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MESO with price predictions
Oct 22, 2026

MESO in +7.36% Uptrend, rising for three consecutive days on October 21, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MESO advanced for three days, in 234 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MESO's RSI Oscillator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

MESO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MESO as a result. In 75 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for MESO turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The 50-day moving average for MESO moved below the 200-day moving average on September 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for MESO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. MESO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.867) is normal, around the industry mean (2.973). P/E Ratio (-28.266) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (29.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (15.504) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
KLRS vs MESO: Fundamental Ratings
KLRS
MESO
OUTLOOK RATING
1..100
5161
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
9378
P/E GROWTH RATING
1..100
818
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KLRS's Valuation (43) in the null industry is somewhat better than the same rating for MESO (93) in the Biotechnology industry. This means that KLRS’s stock grew somewhat faster than MESO’s over the last 12 months.

MESO's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as KLRS (100) in the null industry. This means that MESO’s stock grew similarly to KLRS’s over the last 12 months.

MESO's SMR Rating (94) in the Biotechnology industry is in the same range as KLRS (98) in the null industry. This means that MESO’s stock grew similarly to KLRS’s over the last 12 months.

MESO's Price Growth Rating (78) in the Biotechnology industry is in the same range as KLRS (93) in the null industry. This means that MESO’s stock grew similarly to KLRS’s over the last 12 months.

KLRS's P/E Growth Rating (8) in the null industry is in the same range as MESO (18) in the Biotechnology industry. This means that KLRS’s stock grew similarly to MESO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KLRSMESO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (KLRS: $2.02 vs. MESO: $12.55)
Brand notoriety: KLRS and MESO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KLRS: 127% vs. MESO: 129%
Market capitalization -- KLRS: $47.37M vs. MESO: $1.63B
KLRS [@Biotechnology] is valued at $47.37M. MESO’s [@Biotechnology] market capitalization is $1.63B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KLRS’s FA Score shows that 1 FA rating(s) are green while MESO’s FA Score has 1 green FA rating(s).

  • KLRS’s FA Score: 1 green, 4 red.
  • MESO’s FA Score: 1 green, 4 red.
According to our system of comparison, KLRS is a better buy in the long-term than MESO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KLRS’s TA Score shows that 2 TA indicator(s) are bullish while MESO’s TA Score has 4 bullish TA indicator(s).

  • KLRS’s TA Score: 2 bullish, 2 bearish.
  • MESO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KLRS is a better buy in the short-term than MESO.

Price Growth

KLRS (@Biotechnology) experienced а -5.16% price change this week, while MESO (@Biotechnology) price change was -10.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

KLRS is expected to report earnings on Nov 11, 2026.

MESO is expected to report earnings on Nov 25, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KLRS
Daily Signal:
Gain/Loss:
MESO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

KLRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KLRS
1D Price
Change %
KLRS100%
-1.49%
PTHS - KLRS
43%
Loosely correlated
+4.76%
RCKT - KLRS
30%
Poorly correlated
+5.00%
ARVN - KLRS
29%
Poorly correlated
+2.18%
CGEN - KLRS
29%
Poorly correlated
-7.55%
MESO - KLRS
28%
Poorly correlated
-2.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RLMD3.290.08
+2.49%
Relmada Therapeutics
DOMH1.91-0.01
-0.78%
Dominari Holdings
FJP73.66-1.22
-1.63%
First Trust Japan AlphaDEX Fund (FJP)
ETHB30.66-1.44
-4.49%
iShares Staked Ethereum Trust ETF (ETHB)
ALNT86.18-11.28
-11.57%
Allient